Research Analysts Issue Forecasts for JSPR FY2025 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Jasper Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings per share of ($4.24) for the year. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.15).

Several other brokerages have also weighed in on JSPR. Royal Bank of Canada decreased their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday, January 9th. HC Wainwright decreased their price target on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, January 10th. JMP Securities restated a “market outperform” rating and set a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. Finally, BMO Capital Markets assumed coverage on Jasper Therapeutics in a research report on Friday, December 6th. They issued an “outperform” rating and a $63.00 target price for the company. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $67.75.

Jasper Therapeutics Trading Up 3.4 %

JSPR stock opened at $5.70 on Wednesday. The company has a market capitalization of $85.50 million, a P/E ratio of -1.20 and a beta of 2.18. The firm has a 50 day simple moving average of $18.62 and a 200-day simple moving average of $19.34. Jasper Therapeutics has a twelve month low of $5.25 and a twelve month high of $31.01.

Institutional Investors Weigh In On Jasper Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in shares of Jasper Therapeutics during the third quarter valued at $251,000. Samsara BioCapital LLC boosted its stake in Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after purchasing an additional 59,642 shares during the period. Wellington Management Group LLP bought a new position in Jasper Therapeutics in the 3rd quarter worth about $447,000. Ally Bridge Group NY LLC increased its stake in shares of Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after purchasing an additional 180,852 shares during the period. Finally, FMR LLC bought a new stake in shares of Jasper Therapeutics during the third quarter valued at approximately $722,000. 79.85% of the stock is owned by institutional investors and hedge funds.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.